Phase III CAPItello-281 trial: positive results for PTEN mutated prostate cancer for capivasertib

[Maxone73]

Truqap (capivasertib), an AKT inhibitor, combined with abiraterone and androgen deprivation therapy (ADT) has shown promise in treating men with a specific subtype of prostate cancer called PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).

The Phase III CAPItello-281 trial showed that the Truqap combination significantly improved radiographic progression-free survival (rPFS) compared to abiraterone and ADT with a placebo. Although overall survival (OS) data is not yet mature, early analysis indicates a potential improvement in OS.

So, brothers, fight on!!

prostatewarriors.com/2024/1...

[StayingOptimistic]

Thanks very much Maxone. I am very excited to hear that. I am metastatic ( by psma scans) and HS. I do have a genetic mutation PTEN. tumor suppression gene loss PTEN. Do you think this applies to me?

[Maxone73 in reply to StayingOptimistic]

Yes!

[Cactus297]

Thank you for sharing the good news!🙏🏻